Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 13 patents granted in the last 365 days
Instrumentation Laboratory Company manages 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are assigned to 4 distinct examiners across 4 distinct art units. This one-to-one ratio between actions, examiners, and units suggests that each application is undergoing a separate review process.
KANAAN, MAROUN P is the busiest examiner for the portfolio, with 1 pending office action. With 4 distinct examiners involved, the prosecution strategy must be highly adaptable to different individual styles. The applicant should be prepared to navigate the specific requirements of the 4 distinct art units to advance these pending office actions.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (25%) |
| §103 only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KANAAN, MAROUN P | 1 | 62.7% | +31.7% |
| GOUGH, TIFFANY MAUREEN | 1 | 31.7% | +46.5% |
| TICHY, JENNIFER M.H. | 1 | 64.6% | +34.4% |
| MARCSISIN, ELLEN JEAN | 1 | 34.6% | +49.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 14663560 | BIOASSAY SYSTEM AND METHOD FOR DETECTING ANALYTES IN BODY FLUIDS | MARCSISIN, ELLEN JEAN | 139d overdue |
| 18528941 | BUILDING AND EXECUTING A MEDICAL ALGORITHM | KANAAN, MAROUN P | 41d |
| 17150454 | LUPUS ANTICOAGULANT (LA) MIXING METHOD AND KIT WITH REDUCED FACTOR DEFICIENCY EFFECT AND REDUCED INHIBITOR INTERFERENCE FOR IDENTIFYING LA ASSOCIATED WITH ANTIPHOSPHOLIPID SYNDROME | TICHY, JENNIFER M.H. | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 14663560 | BIOASSAY SYSTEM AND METHOD FOR DETECTING ANALYTES IN BODY FLUIDS | MARCSISIN, ELLEN JEAN | 139d overdue |
| 18528941 | BUILDING AND EXECUTING A MEDICAL ALGORITHM | KANAAN, MAROUN P | 41d |
| 18098422 | IDENTIFYING DIRECT ORAL FACTOR XA INHIBITORS | GOUGH, TIFFANY MAUREEN | 84d |
| 17150454 | LUPUS ANTICOAGULANT (LA) MIXING METHOD AND KIT WITH REDUCED FACTOR DEFICIENCY EFFECT AND REDUCED INHIBITOR INTERFERENCE FOR IDENTIFYING LA ASSOCIATED WITH ANTIPHOSPHOLIPID SYNDROME | TICHY, JENNIFER M.H. | — |
| Art Unit | Apps |
|---|---|
| 3687 | 1 |
| 1651 | 1 |
| 1653 | 1 |
| 1677 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18528941 | BUILDING AND EXECUTING A MEDICAL ALGORITHM | KANAAN, MAROUN P | 3687 | §101§103 | Final Rejection | 41d | Pending | Dec 05, 2023 |
| 18098422 | IDENTIFYING DIRECT ORAL FACTOR XA INHIBITORS | GOUGH, TIFFANY MAUREEN | 1651 | §103 | Non-Final OA | 84d | Pending | Jan 18, 2023 |
| 17150454 | LUPUS ANTICOAGULANT (LA) MIXING METHOD AND KIT WITH REDUCED FACTOR DEFICIENCY EFFECT AND REDUCED INHIBITOR INTERFERENCE FOR IDENTIFYING LA ASSOCIATED WITH ANTIPHOSPHOLIPID SYNDROME | TICHY, JENNIFER M.H. | 1653 | §103§112 | Non-Final OA | — | Pending | Jan 15, 2021 |
| 14663560 | BIOASSAY SYSTEM AND METHOD FOR DETECTING ANALYTES IN BODY FLUIDS | MARCSISIN, ELLEN JEAN | 1677 | §103§112 | Final Rejection | 139d overdue | Pending | Mar 20, 2015 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInstrumentation Laboratory Company has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
Maroun P Kanaan has the most, with 1 of Instrumentation Laboratory Company's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
